Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors

Over half of patients with BRCA1-deficient cancers do not respond to treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. In this study, we report that a combination of 53BP1 and BRCA1 may serve as a biomarker of PARP inhibitor sensitivity. Based on the mRNA levels of four homologous recomb...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Acta Pharmacol Sin
Autori principali: Yang, Zhong-min, Liao, Xue-mei, Chen, Yi, Shen, Yan-yan, Yang, Xin-ying, Su, Yi, Sun, Yi-ming, Gao, Ying-lei, Ding, Jian, Zhang, Ao, He, Jin-xue, Miao, Ze-hong
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2017
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519258/
https://ncbi.nlm.nih.gov/pubmed/28414200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2017.8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi